MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MGTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.04B
- P/E (TTM)
- 12.44
- EPS (TTM)
- $0.87
- Dividend yield
- None
- 52-week range
- 6.62 – 15.35
- Day range
- 10.32 – 11.01
- Volume / Avg
- 2.31M / 773.36K
- Beta
- —
- Shares outstanding
- 96.04M
52-week range
MGTX stock today
Shares of MeiraGTx (MGTX) finished higher on Oct 7 at $10.82, a gain of 2.08% or $0.22 per share, versus the S&P 500's 0.22% decline. Volume was 3.0x the average at 2.31M shares, a sign of unusually heavy trading. At this level, MGTX sits in the middle of its 52-week range of $6.62 to $15.35: 29.5% below the high, set on Jul 7, 2026 and 63.4% above the low.
MGTX is up 36.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 27.4%. MeiraGTx trades at 12.4x its trailing twelve-month earnings per share of $0.87.
Summary generated from market data by MetaCap's automated system. Methodology
About MeiraGTx
Company profileMeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Alexandria Forbes Ph.D.
- Headquarters
- New York, NY
- Employees
- 393
- IPO year
- 2018
- Website
- meiragtx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$27.75+156.47%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
MGTX news
All MGTX newsMeiraGTx peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LTGOLatigo Biotherapeutics Inc. | 15.52 | -4.55% | $1.03B | vs MGTX |
| SVRASavara Inc. | 4.88 | +4.95% | $1.00B | vs MGTX |
| AKTSAktis Oncology Inc. | 18.00 | +0.78% | $1.00B | vs MGTX |
| BCAXBicara Therapeutics Inc. | 16.42 | -0.85% | $1.09B | vs MGTX |
| TRAXFirst Tracks Biotherapeutics Inc. | 30.59 | -2.55% | $1.09B | vs MGTX |
| JANXJanux Therapeutics Inc. | 17.92 | +6.73% | $1.10B | vs MGTX |
| LBRXLB Pharmaceuticals Inc | 34.16 | -0.29% | $1.10B | vs MGTX |
| MNKDMannKind Corporation | 3.45 | -7.01% | $1.11B | vs MGTX |
Indexes, lists and sector
Appears in lists
MeiraGTx stock FAQ
What is MeiraGTx's stock price today?
MGTX last traded at $10.82 as of Oct 7, 4:00 PM EDT, up 2.08% on the day. Prices are delayed at least 15 minutes.
What is MGTX's P/E ratio?
MGTX trades at a trailing P/E ratio of 12.44.
Who is MeiraGTx's CEO?
Dr. Alexandria Forbes Ph.D. is the chief executive officer of MeiraGTx Holdings plc, which has about 393 employees.
What is the MGTX 52-week high?
The 52-week high for MGTX is $15.35 and the 52-week low is $6.62. The stock is currently 29.5% below its high.